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ABSTRACT: Human factor Va (hfVa) is the important regulatory
subunit of prothrombinase. Recent modeling data have suggested a
critical role for amino acid Arg701 of hfVa for human prothrombin
(hPro) activation by prothrombinase. Furthermore, it has also been
demonstrated that hfVa has a diﬀerent eﬀect than that of bovine fVa on
prethrombin-1 activation by prothrombinase. The diﬀerence between
the two cofactor molecules was also found within the Asn700−Arg701
dipeptide in the human factor V (hfV) molecule, which is replaced by
the Asp−Glu sequence in bfV. As a consequence, we produced a
recombinant hfV (rhfV) molecule with the substitution 700NR701→DE.
rhfVNR→DE together with the wild-type molecule (rhfVWT) were
expressed in COS7 cells, puriﬁed, and tested for their capability to
function within prothrombinase. Kinetic studies showed that the Kd of
rhfVaNR→DE for human fXa as well as the kcat and Km of
prothrombinase made with rhfVaNR→DE for hPro activation were similar to the values obtained following hPro activation by
prothrombinase made with rhfVaWT. Remarkably, sodium dodecyl sulfate polyacrylamide gel electrophoresis analyses of hPro
activation time courses demonstrated that the rate of cleavage of hPro by prothrombinase reconstituted with rhfVaNR→DE was
signiﬁcantly delayed with substantial accumulation of meizothrombin, and delayed thrombin generation, when compared to
activation of hPro by prothrombinase made with rhfVaWT. These unanticipated results provide signiﬁcant insights on the role of
the carboxyl-terminal end of the heavy chain of hfVa for hPro cleavage and activation by prothrombinase and show that residues
700
NR701 regulate at least in part the enzyme−substrate/product interaction during ﬁbrin clot formation.

■

INTRODUCTION

Human factor V (hfV) is present in blood at 20 nM as a single
chain protein with a high molecular weight (Mr of 330 000). It is
composed of three protein domains (A−C) that will produce a
two-subunit protein made of light and heavy chains following
cleavage and activation by thrombin at Arg709, Arg1018, and
Arg1545 (Figure 1).10−13 The 105 000 heavy chain is bound to the
74 000 light chain through hydrophobic interactions. These
hydrophobic interactions are only exposed on the hfV/hfVa
molecule following its interaction with calcium ions ( Figure 1).14
Mature hPro is an inactive zymogen with a Mr of 72 000 that
has undergone substantial post-translational modiﬁcations
before being secreted by the liver. Included in these
modiﬁcations is the carboxylation of several glutamic acids at
the NH2-terminus, a process that is vitamin K-dependent and is
essential for proper binding of hPro to the procoagulant surface,
which in turn is required for timely and eﬃcient activation by
prothrombinase. Thrombin has two charged regions (anion
binding exosite I (ABE-I) and anion binding exosite II (ABE-II)),
which are vital for its function. ABE-I is responsible for

Human factor Va (hfVa) is the important regulatory subunit of
prothrombinase that controls the rate of human prothrombin
(hPro) activation by prothrombinase during hemostasis.1 This
process is a highly regulated event, which involves various
enzymatic entities that participate in a series of reactions.
Prothrombinase activation of hPro is the penultimate step in the
coagulation cascade implemented after any event that exposes a
procoagulant membrane surface.2 In vivo, the procoagulant
membrane surface is usually delivered by activated platelets and/
or endothelial cells.3,4 Human factor Xa (hfXa), the enzymatic
subunit of prothrombinase, can itself activate hPro after two
consecutive cleavages at Arg271 and Arg320 to yield prethrombin-2
(Pre2). Association of the regulatory molecule hfVa with fXa will
lead to the establishment of the prothrombinase complex, and a
switch of the order of cleavages (Arg320 followed by Arg271) will
yield the intermediate meizothrombin (MzT). This complex
increases the enzymatic activity of hfXa by 300 000-fold.5−9 It is
believed that the regulatory subunit of prothrombinase, hfVa, has
a substantial eﬀect on this reversal of cleavages, thus aiding in
presenting Arg320 of the substrate to the catalytic subunit of
prothrombinase.
© 2017 American Chemical Society
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Figure 1. hfV. Left panel, hfV structure; hfV is composed of three A domains (red), two C domains (light blue), and a B region (yellow). hfV is activated
following three sequential cleavages by α-thrombin at Arg709, Arg1018, and Arg1545. These cleavages are required to release the active cofactor composed
of heavy (amino acids 1−709) and light (amino acids 1546−2196) chains noncovalently associated in the presence of divalent metal ions, and two
activation fragments. The carboxyl-terminal portion of the heavy chain contains an acidic hirudin-like amino acid region that is important for cofactor
function.26 Adjacent to this region are also the amino acids Asn700 and Arg701, which are important for cofactor activity.33 The amino acid substitutions
within the heavy chain are indicated together with the designation for the recombinant mutant hfV molecule created and used throughout the article.
Right panel; electrophoretic analyses of rhfVNR→DE and rhfVaNR→DE molecules. rhfVNR→DE was activated with thrombin as described in the Experimental
Section and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following transfer to a poly(vinylidene diﬂuoride)
(PVDF) membrane, immunoreactive fragments were detected with the monoclonal antibodies αHFVaHC17 (recognizing an epitope on the heavy chain
of the cofactor between amino acid residues 307−506) and αHFVaHC9 (recognizing the light chain). The positions of the heavy/light chains of hfVa are
shown on the right. Lane 1, rhfVNR→DE; lane 2, rhfVaNR→DE.

Table 1. Cofactor Properties of rhfVa Molecules
rhfVa species
WT

rhfVa
rhfVaNR→DE
a

clotting activity (U/mg)
3631 ± 237
210 ± 35

decrease (-fold)

KDapp (nM)

Km (μM)

kcat (min−1)a

kcat/Km (M−1·s−1) × 108

decrease (-fold)

17.3

0.48 ± 0.10
0.75 ± 0.30

0.207 ± 0.01
0.214 ± 0.03

2688 ± 47
2641 ± 87

2.1
2.0

1.05

kcat = Vmax/[enzyme] (in the presence of fVa); the enzyme concentration of prothrombinase was 10 pM for all experiments.

cofactor on Pre1 was shown to be conﬁned within the very last
portion of the COOH-terminus of the hfVa heavy chain. A
prominent diﬀerence in amino acid between the two cofactor
molecules in that region is restricted to positions 700−701 where
an Asn−Arg dipeptide in hfVa is replaced by the Asp−Glu
sequence in bfVa,34−36 resulting in a total replacement of the net
positive charge with two negative charges. Interestingly, very
recently modeling data have shown that Arg701 of hfVa interacts
with Glu345 of hPro.32 The work undertaken herein proposes to
evaluate the signiﬁcance of the 700Asn−Arg701 dipeptide of the
hfVa heavy chain for enzyme−substrate recognition/interaction
during hPro activation by prothrombinase. A substantial amino
acid change, and a change in charge, in this portion of the
cofactor will allow for an in-depth study of this very important
contributor of prothrombinase. We directly tested the function
of this portion of the heavy chain by using a recombinant
molecule and several speciﬁc assays. The remarkable and
unpredicted results presented herein solidify the notion that
the acidic carboxyl-terminus of the heavy chain of hfVa is critical
for proper prothrombinase function and dictates the timely
interaction of hFVa with the substrate/product, as recently
suggested by modeling studies of prothrombinase.32

interacting with a plethora of proteins participating in the
coagulation cascade like hfV, hfVa, and ﬁbrinogen. ABE-II is the
heparin-binding site.15−20
The Kd value of the hfVa−hPro interaction is 1 μM.21,22 hfVa
provides binding sites for proexosite 1 and the Gla domain of
hPro, explaining one of the possible mechanisms by which the
cofactor functions to increase enzyme eﬃciency.20,23 It has been
proven that several acidic amino acids at the very end of the heavy
chain of hfVa are vital for hfVa cofactor activity24−30 and
participate in the interaction of hPro with prothrombinase. It has
been proposed that amino acids from the region 680−709 are
required for proper interaction and catalysis of hPro by hfXa
within prothrombinase.26,28,31 Further, we have hypothesized
that these acidic residues may be involved in the direct binding of
hfVa with hPro and/or thrombin through positively charged
amino acids. This substantial increase in enzymatic activity
resulting in rapid thrombin generation is credited to the precise
and unique interactions of the cofactor with speciﬁc amino acids
aﬃliated with both membrane-bound hfXa and membranebound hPro, as recently demonstrated.32 Accordingly, introduction of the nonenzymatic cofactor into prothrombinase equips
the organism with the coagulation artillery necessary for the
explosive arrest of vasculature bleeding.
A substantial diﬀerence was demonstrated when bovine factor
Va (bfVa) or hfVa were used to activate prethrombin-1 (Pre1) by
prothrombinase.33 The reason for the diﬀerent eﬀect of the

■

RESULTS AND DISCUSSION
Transient Expression and Analysis of rhfVNR→DE. To
ascertain the signiﬁcance of the amino acid region 700−701 of
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hfVa, we made a recombinant mutant factor V molecule (rhfV)
with the substitution NR→DE (Figure 1, left panel). Figure 1,
right panel, shows a typical quality control practice. The data
show the makeup of rhfVNR→DE before (right panel, lane 1) and
after (right panel, lane 2) activation by thrombin. After treatment
with thrombin, no rhfVNR→DE was apparent on the gel, whereas
fragments with the molecular weights of the two subunits were
visible (a fragment of Mr 105 000 representing the heavy chain
and a fragment of Mr 74 000 representing the light chain, both
identiﬁed with monoclonal antibodies speciﬁcally made against
each subunit). Clotting activity assays illustrated the fact that
activation of rhfVWT gave rise to a molecule with similar activity
to that of the plasma-derived molecule (Table 1).26,36 In contrast,
using analogous experimental conditions, rhfVaNR→DE had ∼17fold less clotting activity (Table 1). These results are unexpected,
and they show that amino acids 700−701 are essential for
expression of rhfVa clotting activity.
Characterization of rhfVa Molecules through Kinetic
Experiments. The kinetic eﬀect that hfVa has on the
prothrombinase-mediated activation of hPro has been wellstudied over the past 50 years, but it is still not properly
understood, and no speciﬁc molecular role has yet been assigned
to the cofactor. Research with discontinuous assays using a
chromogenic substrate for thrombin revealed that when hfVa is
combined into the prothrombinase complex, the overall increase
in activity of the enzymatic complex for the activation of hPro,
compared to cleavage and activation of hPro by fXa alone, is
substantially increased, making the two-subunit enzyme one of
the most proﬁcient catalysts known in the human body and
similar to several other enzymes required for survival such as
superoxide dismutase, catalase, and carbonic anhydrase. This
signiﬁcant increase in aﬃnity of prothrombinase toward its
substrate is attributed to tighter binding of the enzyme complex
to hPro because of its localization on the membrane surface by
hfVa. Thus, hfVa enhances thrombin generation by facilitating
initial cleavage at Arg320 on hPro by hfXa that provides for the
generation of an important enzymatic intermediate, MzT, with
demonstrated anticoagulant activity.
We next evaluated the ability of rhfVaNR→DE to bind rhfXa and
form prothrombinase (Table 1). The data show that rhfVaWT has
similar aﬃnity for fXa as its plasma counterpart.26,36 Similarly,
rhfVaNR→DE has comparable aﬃnity for plasma-derived fXa,
which is approximately the same as the aﬃnity of rhfVaWT for fXa.
These data demonstrate that residues 700−701 from the heavy
chain of fVa, while being a major contributor for optimal
expression of fVa clotting activity, do not contribute to the
interaction between the cofactor and fXa. We subsequently
assessed the consequence of the mutation on the Km and kcat of
the enzyme. The resulting kinetic graphs are shown in Figure 2,
and the constants of the enzyme made with either rhfVaWT or
rhfVaNR→DE are provided in Table 1. The results surprisingly
demonstrate that the amino acid substitutions had no substantial
eﬀect on either the Km of the reaction or on the catalytic
eﬃciency of prothrombinase made with rhfVaNR→DE (Figure 2,
Table 1). Compared to the data using the clotting assays, these
unexpected results are somehow puzzling, and thus far
demonstrate that the NR→DE substitution only aﬀects the
clotting activity of rhfVaNR→DE. The kinetic data alone do not
provide an explanation for the impaired clotting activity of
rhfVaNR→DE.
Visualization of the Activation Pathway. Because of the
unexpected and contradictory results obtained in the activity
assays (clotting vs kinetic assay), and to better appreciate the

Figure 2. Raw data used for the determination of the kinetic parameters
of prothrombinase complex assembly and function. Initial rates of
thrombin generation were determined as described in the Experimental
Section. The data obtained were ﬁt by nonlinear regression analysis to
the Michaelis−Menten equation to obtain the K m and V max.
Prothrombinase assembled with rhfVaWT is shown by ﬁlled squares
(R2 = 0.98, three titrations with two diﬀerent preparations of rhfVaWT)
whereas prothrombinase assembled with rhfVaNR→DE is depicted by
ﬁlled triangles (R2 = 0.96, three titrations with three diﬀerent
preparations of rhfVaNR→DE). The values of the Km and Vmax/ET
(=kcat) extracted directly from these graphs are listed in Table 1.

reason for the dearth in clotting activity of rhfVaNR→DE, we
evaluated hPro activation by SDS-PAGE. The results display a
considerable and signiﬁcant delay in hPro activation by
prothrombinase made with rhfVaNR→DE when related to cleavage
of hPro by prothrombinase reconstituted with rhfVaWT with
MzT lingering very late in the reaction and with little visible
thrombin formation (Figure 3). Densitometry scanning of the
SDS-PAGE results presented in Figure 3 established a 10-fold
delay in hPro cleavage by prothrombinase made with
rhfVaNR→DE when matched to the consumption of hPro with
prothrombinase assembled with rhfVaWT (Figure 4, Table 2).
Furthermore, it is clearly visible on the gels that when hPro is
cleaved by prothrombinase reconstituted with rhfVaNR→DE, there
is lingering of MzT during the activation time course. A peak for
MzT is noticeable at 60 s when hPro is cleaved by
prothrombinase made with rhfVaWT, and a peak for MzT is
present at ∼600 s when hPro is processed by prothrombinase
made with rhfVaNR→DE (Figure 4). These data can explain the
paradoxical ﬁndings above and the apparent discrepancy
between the clotting and kinetic assays, and they undeniably
suggest that the slow accumulation of MzT is responsible for the
poor clotting activity observed with rhfVaNR→DE. These data also
verify our previous ﬁndings,26 and demonstrate that MzT can
counterbalance the dearth of thrombin activity in the
chromogenic test because its catalytic activity toward the
chromogenic substrate used in our study is much higher than
that of thrombin, as previously demonstrated.26,37,38
Our data clearly show that although prothrombinase
assembled with rhfVaNR→DE has similar Km and kcat as
prothrombinase assembled with rhfVaWT, the clotting activity
of rhfVNR→DE is severely impaired. In addition, visualization of
the cleavage pattern of hPro activation by prothrombinase
assembled with rhfVaNR→DE demonstrated a signiﬁcantly diﬀerent pattern of activation from the gels analyzing hPro activation
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Figure 3. Analysis of the activation of plasma-derived hPro by prothrombinase. Plasma-derived hPro (1.4 μM) was incubated in diﬀerent mixtures with
PCPS vesicles (20 μM), and prothrombinase was assembled with either wild-type rhfVa (panel A, 20 nM) or rhfVaNR→DE (panel B, 20 nM), as described
in the Experimental Section. At selected time intervals, aliquots of the reactions were withdrawn and treated as described in the Experimental Section. M
represents the lane with the molecular weight markers (from top to bottom): Mr 98 000, Mr 64 000, Mr 50 000, Mr 36 000, Mr 22 000. Lanes 1−17
represent samples from the reaction mixture before (0 min) the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240 s, 5, 6, 10, and 20
min, respectively, following the addition of fXa. The hPro-derived fragments are shown as follows: Pro (hPro, amino acid residues 1−579); P1
(prethrombin-1, amino acid residues 156−579); F1•2-A (fragment 1•2-A chain, amino acid residues 1−320); F1•2 (fragment 1•2, amino acid residues
1−271); P2 (prethrombin-2, amino acid residues 272−579); B (B chain of α-thrombin, amino acid residues 321−579). F1 (fragment 1, amino acid
residues 1−155); F2 (fragment 2, amino acid residues 156−271).

Table 2. Rate of Various Substrate Cleavage by
Prothrombinase

substrate
plasma-derived
prothrombin
rMZ-II
rP2-II
FPR-meizothrombin
prethrombin-1

prothrombinase
assembled with rhfVaWT
(moles consumed·s−1·
(mole factor Xa)−1)

prothrombinase
assembled with
rhfVaNR→DE (moles
consumed·s−1·(mole
factor Xa)−1)

26.7 ± 2.5 (0.99)a

2.6 ± 0.17 (0.99)a

11.8 ± 0.9 (0.99)
3.0 ± 1.5 (0.86)
56.8 ± 0.8 (0.99)
46.7 ± 3.3 (0.99)

1.7 ± 0.2 (0.99)
1.5 ± 0.4 (0.97)
19.4 ± 1.7 (0.99)
12.1 ± 12 (0.77)

The numbers in parentheses represent the goodness of ﬁt for the
ﬁtting of the data to a ﬁrst-order exponential decay.
a

by prothrombinase assembled with rhfVaWT. Thus, if we had
limited our initial analysis of the mutant molecule to
prothrombinase assays using puriﬁed proteins and a chromogenic substrate without using clotting assays and gel electrophoresis analysis, as is the case in the majority of the studies
assessing mutations in the hfVa molecule, we would have missed
and dismissed the particular critical regulatory function of this
region of the molecule, as was the case on multiple occasions in
the past.39
Activation of Recombinant Mutant hPro, FPR-MzT, and
Pre1 by Prothrombinase Assembled with rhfVaNR→DE. The
data obtained thus far show that both cleavages at Arg320 and
Arg 271 in hPro appeared to be impaired when using
prothrombinase made with rhFVaNR→DE. To quantify the level
of impairment of each of the cleavages separately in hPro that
were speciﬁcally aﬀected by the 700NR→DE701 substitution, we

Figure 4. Reaction proﬁles for the activation of hPro by prothrombinase.
Progress curves for products and reactants for the activation of hPro by
prothrombinase assembled with rhfVa WT (ﬁlled symbols) or
rhfVaNR→DE (open symbols) were obtained by quantitative densitometry of the gels shown in Figure 3A,B, as described in the Experimental
Section. The graphs illustrate the disappearance of hPro (circles), the
transient formation of MzT (squares), and the accumulation of the B
chain of α-thrombin (triangles). The lines for the disappearance of hPro
were drawn according to the equation of a one phase exponential decay
(rhfVaWT, R2 = 0.99, and rhfVaNR→DE, R2 = 0.99). The lines depicting the
formation of MzT and the accumulation of the B chain of α-thrombin
were arbitrarily drawn. Additional data points extending to 1 h of
incubation have been omitted for clarity.
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employed recombinant hPro molecules with only one site
speciﬁc for prothrombinase cleavage (Arg320 for rMZ-II and
Arg271 for rP2-II).40
The results provided in Figure 5A illustrate a substantial delay
in the rate of cleavage of rMZ-II by prothrombinase reconstituted

Figure 6. Analysis of rMZ-II consumption by prothrombinase
assembled with rhfVa molecules. The gel shown in Figure 5 (A) was
scanned and hPro consumption was recorded as described in the
Experimental Section. Following scanning densitometry, the data
representing recombinant mutant hPro consumption as a function of
time (s) were plotted using nonlinear regression analysis according to
the equation representing a ﬁrst-order exponential decay using the
software Prizm (GraphPad, San Diego, CA), as described in the
Experimental Section. Prothrombinase was assembled with rhfVaWT
(ﬁlled circles) or rhfVaNR→DE (open circles). The apparent ﬁrst-order
rate constant, k (s−1) was obtained directly from the ﬁtted data, and the
resulting numbers representing recombinant mutant hPro consumption
are reported in Table 2.

Figure 5. Analysis of the activation of rMZ-II and rP2-II. rMZ-II (1.4
μM, panel A) and rP2-II (1.4 μM, panel B) were incubated in diﬀerent
mixtures with PCPS vesicles (20 μM), DAPA (3 μM), and rhfVaWT (20
nM) or rhfVaNR→DE (20 nM). The reaction was started by the addition
of fXa, and the samples were treated as detailed in the Experimental
Section. Lanes 1−9 represent samples of the reaction mixture following
incubation of prothrombinase assembled with rhfVaWT with rMZ-II or
rP2-II before (lane 1) or following 1, 3, 5, 10, 20, 45, 60, and 120 min of
incubation with fXa, respectively. Lanes 10−18 represent samples of the
reaction mixture following incubation of prothrombinase assembled
with rhfVaNR→DE with rMZ-II or rP2-II before (lane 10) or following 1,
3, 5, 10, 20, 45, 60, and 120 min of incubation with fXa, respectively.
Positions of hPro-derived fragments are indicated to the right, as
detailed in the legend of Figure 3. For easy reading of the article, the
rhfVa species used for the reconstitution of prothrombinase are also
shown.

activation of hPro or rMZ-II following cleavage at Arg320 is more
sensitive to the mutation in rhfVa than the rate of activation of
hPro or rP2-II following cleavage at Arg271. To understand the
eﬀect of the 700NR701→DE mutations on the cleavage of hPro at
Arg271 alone after the conformational alteration occurring in hPro
following cleavage at Arg320,41 we assessed the change in the rate
of cleavage of FPR-meizothrombin (FPR-MzT) by prothrombinase reconstituted with rhfVaWT or rhfVaNR→DE (Figure 7). The
results demonstrate a considerable delay for cleavage of FPRMzT at Arg271 by prothrombinase made with rhfVaNR→DE (panel
B) when related to the reaction that is catalyzed by
prothrombinase reconstituted with rhfVaWT (panel A). Densitometry scanning analysis of the concentration of fragment 1•2A conﬁrmed an ∼3-fold delay in cleavage of FPR-MzT at Arg271
by prothrombinase made with rhfVaNR→DE (Figure 8, Table 2).
However, it is worth noting that the maximum eﬀect on the rate
of cleavage at Arg271 of MzT credited to the binding of hfVa with
hfXa on a cell/membrane surface is 4-fold.8,9 Thus, the
700
NR 701 →DE mutations in the fVa heavy chain also
considerably impede acceleration for cleavage at this site by
prothrombinase.
To determine the eﬀect of the 700NR701→DE substitutions
within the factor Va heavy chain on the cleavage of hPro at Arg320
alone when the substrate is not associated with the membrane
surface, we compared the rates of activation of Pre1 by
prothrombinase made with rhfVaWT and rhfVaNR→DE (Figure
9). Under the conditions used, the results show a substantial
delay for activation of Pre1 following cleavage at Arg320 by
prothrombinase made with rhfVaNR→DE (panel B) when related
to the reaction catalyzed by prothrombinase reconstituted with

with rhfVaNR→DE (lanes 10−18) when compared to the rate of
activation of rMZ-II by prothrombinase composed with rhfVaWT
(lanes 1−9). Scanning densitometry showed that activation of
rMZ-II is slower by ∼10-fold when prothrombinase is made with
rhfVaNR→DE compared to activation of rMZ-II by prothrombinase composed with rhVaWT (Table 2, Figure 6). A 2-fold slower
hPro rate of activation was also detected when rP2-II was cleaved
by prothrombinase reconstituted with rhfVaNR→DE when
matched to the activation of rP2-II by prothrombinase made
with rhfVaWT (Figure 5B, Table 2). These results support our
data acquired with hPro. Altogether, the data suggest that
prothrombinase-mediated cleavages at Arg320/Arg271 in hPro are
signiﬁcantly delayed when prothrombinase is made with
rhfVaNR→DE. It is also clear, however, that cleavage at Arg320 is
more aﬀected by the substitution in hfVa than cleavage at Arg271.
Examination of the results acquired up until now with plasmaderived and recombinant hPro demonstrates that the rate of
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Figure 8. Analysis of FPR-MzT consumption by prothrombinase
assembled with rhfVa molecules. The gels shown in Figure 7 were
scanned and FPR-MzT consumption was recorded as described in the
Experimental Section. Following scanning densitometry, the data
representing FPR-MzT consumption as a function of time (s) were
plotted using nonlinear regression analysis according to the equation
representing a ﬁrst-order exponential decay using the software Prizm
(GraphPad, San Diego, CA), as described in the Experimental Section.
The apparent ﬁrst-order rate constant k (s−1) was obtained directly from
the ﬁtted data. Prothrombinase was assembled with rhfVaWT (ﬁlled
circles) or rhfVaNR→DE (open circles); factor fXa alone cleavage of FPRMzT is shown by the open squares. The resulting numbers representing
FPR-MzT consumption are reported in Table 2.

Figure 7. Gel electrophoresis analyses for cleavage of FPR-MzT. FPRMzT (1.4 μM) was incubated in diﬀerent mixtures with PCPS vesicles
(20 μM) and rhfVa as described in the legend to Figure 3. The reactions
were started by the addition of fXa, and the samples were further treated,
scanned, and quantiﬁed as detailed in the Experimental Section. Panel A,
prothrombinase assembled with rhfVaWT; panel B, prothrombinase
assembled with rhfVaNR→DE; M represents the lane with the molecular
weight markers (from top to bottom): Mr 50 000, Mr 36 000, Mr 22 000.
Lanes 1−17 represent samples from the reaction mixture before (0 min)
the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220,
and 240 s, 5, 6, 10, and 20 min, respectively, following the addition of
fXa. The hPro-derived fragments are shown as detailed in the legend to
Figure 3. The recombinant rhfVa species used for the reconstitution of
prothrombinase is also shown under each panel.

generating the wrong conclusion that the NR→DE substitution
has negligible or no eﬀect on prothrombinase activity.
The hypothesis that fVa conﬁnes and places hPro in an
optimum position for eﬃcient catalysis by fXa was conﬁrmed by
computational studies with prothrombinase by Shim et al.,32 who
demonstrated that the acidic end of the heavy chain of hfVa is
essential in its ability to capture the serine protease domain of
hPro and reposition the Arg320 cleavage site at an optimal
position for well-timed cleavage by fXa and hPro activation.42
These productive interactions between the acidic amino acids
from the carboxyl-terminal portion of the hfVa heavy chain and
hPro have been repeatedly suggested following experiments with
synthetic peptides and recombinant hfVa molecules.26−28 In
particular, Shim et al. proposed a direct interaction between
Arg701 of fVa and Gln345 of hPro, the latter being only 24 amino
acids away from the crucial activating hPro cleavage site at
Arg320.32 They also proposed a salt bridge between Asp695 of hfVa
and Lys340 of hPro, and between Tyr698 of fVa and Lys474 of
hPro.32 We show that replacement of Arg701 in hfVa by a Glu, and
the subsequent loss of the positive charge, results in a
considerable delay in activating hPro following cleavage at
Arg320. We have also shown repeatedly that Asp695 and Tyr698 are
a part of a peptide portion of the hfVa heavy chain that represents
a control switch for the activity of prothrombinase.27,28 Overall
our experimental data together with the recent computational
model of hfVa clearly establish a proliﬁc interaction between the
acidic carboxyl-terminus of the hfVa heavy chain and several
residues adjacent or nearby to the crucial cleavage site at Arg320 of
hPro for timely thrombin production.

hfVaWT (panel A). Scanning of Pre1 from the gels depicted in
Figure 9 conﬁrmed an ∼4-fold delay in activation of Pre1 at
Arg320 by prothrombinase made with rhfVaNR→DE (Figure 10,
Table 2). As a consequence, the 700NR701→DE mutations in the
rhfVa heavy chain substantially impair activation of Pre1 by
prothrombinase because of an impaired capability for cleavage at
Arg320 even when the substrate (Pre1) is not associated with a
membrane surface.
Thus, because we have studied the consequence of the
mutations on the clotting activity and on the rate of each cleavage
individually, by analyzing activation of rMZ-II, rP2-II, FPR-MzT,
and Pre1 by SDS-PAGE using prothrombinase made with
rhfVaNR→DE, we can determine that both cleavages at Arg320 and
Arg271 are impaired, resulting in MzT being present through the
hPro activation process. In addition, a substantial increase in the
concentration of MzT in our assays (as shown in Figure 4) can
explain the initial inconsistent ﬁndings. The additional MzT
molecules present throughout the time course, while lacking
clotting activity, can compensate for the lack of thrombin activity
in the assays using puriﬁed proteins because the molecule has
augmented amidolytic activity toward chromogenic substrates
that are, in general, used to evaluate thrombin activity, thus
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Figure 10. Analysis of Prethrombin-1 consumption by prothrombinase
assembled with rhfVa molecules. The gels shown in Figure 9 were
scanned and Pre1 consumption was recorded as described in the
Experimental Section. Following scanning densitometry, the data
representing Pre1 consumption as a function of time (s) were plotted
using nonlinear regression analysis according to the equation
representing a ﬁrst-order exponential decay using the software Prizm
(GraphPad, San Diego, CA), as described in the Experimental Section.
The apparent ﬁrst-order rate constant k (s−1) was obtained directly from
the ﬁtted data. Prothrombinase was assembled with rhfVaWT (ﬁlled
circles), rhfVaNR→DE (open circles); cleavage by fXa alone is shown by
open squares. The resulting numbers representing Pre1 consumption
are reported in Table 2.

Figure 9. Gel electrophoresis analyses for cleavage of Prethrombin-1.
Prethrombin-1 was incubated in diﬀerent mixtures with PCPS vesicles
and rhfVa as described previously in detail.20 The reaction and the
samples were further treated, scanned, and quantiﬁed as detailed in the
Experimental Section. Panel A, control, rhfVaWT; panel B, rhfVaNR→DE.
M represents the lane with the molecular weight markers (from top to
bottom): Mr 50 000, Mr 36 000, Mr 22 000. Lanes 1−19 represent
samples from the reaction mixture before and after the addition of fXa as
previously described.20 The hPro-derived fragments are shown as
detailed in the legend to Figure 3. The fragment denoted as P2′ depicts
Pre2 cleaved at Arg284. For easy reading of the article, the rhfVa species
used for the reconstitution of prothrombinase is also shown under each
panel.

■

CONCLUSIONS
The speciﬁc amino acid sequence 700−701 from hfVa is not
strictly conserved among species36 (indicated by the vertical
arrow in Figure 11). Although hfVa has the identical sequence as
higher primates and fVa from horse, all other species shown in
Figure 11 have diﬀerent amino acids at these two positions,
suggesting an important role of these two residues within fVa.
Although there is no eﬀect of the 700NR701→DE mutation in hfVa
on the direct binding of hfVa to hfXa, there is a signiﬁcant eﬀect
of the mutation on hPro activation by prothrombinase
reconstituted with the mutated cofactor molecule, which is
translated by hindered cleavage at both Arg320/Arg271. Consequently, our results strongly suggest that these amino acids are
part of an important sequence that is accountable for the
recognition and interaction of the substrate (Pro) with
prothrombinase within diﬀerent species. Furthermore, the data
presented herein support the notion that Arg701 of the hfVa heavy
chain makes a salt bridge with Glu345 of hPro, thus facilitating and
promoting initial cleavage of hPro at Arg320, which was suggested
by a recent computational model of prothrombinase.32
Collectively, the results strongly suggest that hfVa, the regulatory
subunit of prothrombinase, undeniably controls the activity of
hfXa within the enzymatic complex by directing the enzymatic
subunit toward cleavage at Arg320, and thus actively participates
in the cleavage and activation of hPro by prothrombinase. We
must also conclude that all assays used herein to characterize
rhfVaNR→DE are not redundant, but rather they are compli-

Figure 11. Comparison of the last 20 amino acids from the acidic
carboxyl-terminal portion of the fVa heavy chain. The acidic sequence
from 20 species is illustrated as adapted from ref 36. The special
nomenclature of all species was previously described.36

mentary and a procedural requirement to understand the
structural intricacies of the cofactor and its contributions to the
activity of prothrombinase.

■

EXPERIMENTAL SECTION
Materials and Reagents. Human fV cDNA was obtained
from American Type Tissue Collection (ATCC# 40515 pMT2V, Manassas, VA). The origin of all other chemicals, reagents, and
proteins used by our laboratory is provided elsewhere.36
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Recombinant hPro rMZ-II with only one site for hfXa (i.e.,
Arg320) and hPro rP2-II with only one site for hfXa (i.e., Arg271)
were obtained as detailed previously.40
Mutagenesis and Transient Expression of Recombinant FV Molecules. A mutant hfV molecule mutated at the
COOH-terminus of the heavy chain was produced using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA), and was constructed as previously detailed26 with the
mutagenic primers fVNR→DE mutant: 5′-GATGCTGACTATGATTACCAGGACGAACTGGCTGCAGCATT-3′ (sense)
and 5′-GATTCCTAATGCTGCAGCCAGTTCGTCCTGGTAATCATAGT-3′ (antisense).
Expression of Recombinant Wild-Type and Mutant FV
in Mammalian Cells. Expression in COS-7L cells was
performed as previously detailed,26 and the concentration of
recombinant proteins was obtained by enzyme-linked immunosorbent assay as previously shown.43 The activity of the
recombinant molecules was veriﬁed by clotting assays using fVdeﬁcient plasma.36
Gel Electrophoresis and Western Blotting. SDS-PAGE
analyses were performed using the method of Laemmli.44
Western blotting using poly(vinylidene diﬂuoride) (PVDF)
membranes was performed according to Towbin et al.45
Following transfer to PVDF, fV heavy and light chain(s) were
identiﬁed using the suitable monoclonal and polyclonal antibodies46−49 and chemiluminescence.
Analysis of hPro Activation by Gel Electrophoresis.
hPro molecules (1.4 μM) were incubated with PCPS vesicles (20
μM), DAPA (50 μM), and fVa, and analysis was performed as
detailed elsewhere.26,28,36
Measurement of Rates of hPro Activation. All rhfVa
molecules were activated with human thrombin and tested as
previously detailed using a Thermomax microplate reader
(Molecular Devices, Sunnyvale, CA).31,50
Scanning Densitometry of SDS-PAGE and Calculation
of the Rate of hPro Consumption. Scanning densitometry of
the gels was performed as described in detail elsewhere.50

■

■
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■
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700
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700
NR701→DE activated with thrombin
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hfXa, human factor Xa
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Pre1, prethrombin-1
FPR, Phe-Pro-Arg-Chloromethylketone
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(40) Côté, H. C. F.; Stevens, W. K.; Bajzar, L.; Banfield, D. K.;
Nesheim, M. E.; MacGillivray, T. A. Characterization of a stable form of
human meizothrombin derived from recombinant prothrombin
(R155A, R271A, and R284A). J. Biol. Chem. 1994, 269, 11374−11380.
(41) Bianchini, E. P.; Orcutt, S. J.; Panizzi, P.; Bock, P. E.;
Krishnaswamy, S. Racheting of the substrate from the zymogen to
proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 10099−
10104.
(42) Guinto, E. R.; Esmon, C. T. Loss of prothrombin and of factor Xafactor Va interactions upon inactivation of factor Va by Activated
Protein C. J. Biol. Chem. 1984, 259, 13986−13992.
(43) Singh, L. S.; Bukys, M. A.; Beck, D. O.; Kalafatis, M. Amino acids
Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for
expression of cofactor activity. J. Biol. Chem. 2003, 278, 28335−28345.
(44) Laemmli, U. K. Nature 1970, 227, 680−685.
(45) Towbin, H.; Staehlin, T.; Gordon, J. Proc. Natl. Acad. Sci. U.S.A.
1979, 76, 4350−4354.
(46) Kalafatis, M.; Bertina, R. M.; Rand, M. D.; Mann, K. G.
Characterization of the molecular defect in factor VR506Q. J. Biol. Chem.
1995, 270, 4053−4057.
(47) Kalafatis, M.; Haley, P. E.; Lu, D.; Bertina, R. M.; Long, G. L.;
Mann, K. G. Proteolytic events that regulate factor V activity in whole
plasma from normal and activated protein C (APC)-resistant individuals
during clotting: an insight into the APC-resistance assay. Blood 1996, 87,
4695−4707.
(48) van’t Veer, C.; Kalafatis, M.; Bertina, R. M.; Simioni, P.; Mann, K.
G. Increased tissue factor-initiated prothrombin activation as a result of
the Arg506 –> Gln mutation in factor VLEIDEN. J. Biol. Chem. 1997,
272, 20721−20729.
(49) van’t Veer, C.; Golden, N. J.; Kalafatis, M.; Mann, K. G. Inhibitory
mechanism of the protein C pathway on tissue factor-induced thrombin
generation. Synergistic effect in combination with tissue factor pathway
inhibitor. J. Biol. Chem. 1997, 272, 7983−7994.
(50) Bukys, M. A.; Orban, T.; Kim, P. Y.; Beck, D. O.; Nesheim, M. E.;
Kalafatis, M. The structural integrity of anion binding exosite-I of
thrombin is required and sufficient for timely cleavage and activation of
factor V and factor VIII. J. Biol. Chem. 2006, 281, 18569−18580.

(16) Anderson, P. J.; Nesset, A.; Dharmawardana, K. R.; Bock, P. E.
Role of proexosite I in factor Va-dependent substrate interactions of
prothrombin activation. J. Biol. Chem. 2000, 275, 16435−16442.
(17) Hibbard, L. S.; Nesheim, M. E.; Mann, K. G. Progressive
development of a thrombin inhibitor binding site. Biochemistry 1982, 21,
2285−2292.
(18) Martin, P. D.; Malkowski, M. G.; Box, J.; Esmon, C. T.; Edwards,
B. F. New insights into the regulation of the blood clotting cascade
derived from the X-ray crystal structure of bovine meizothrombin des F1
in complex with PPACK. Structure 1997, 5, 1681−1693.
(19) Chen, L.; Yang, L.; Rezaie, A. R. Proexosite-1 on prothrombin is a
factor Va-dependent recognition site for the prothrombinase complex. J.
Biol. Chem. 2003, 278, 27564−27569.
(20) Bukys, M. A.; Orban, T.; Kim, P. Y.; Nesheim, M. E.; Kalafatis, M.
The interaction of fragment 1 of prothrombin with the membrane
surface is a prerequisite for optimum expression of factor Va cofactor
activity within prothrombinase. Thromb. Haemostasis 2008, 99, 511−
522.
(21) Esmon, C. T.; Owen, W. G.; Duiguid, D. L.; Jackson, C. M. The
action of thrombin on blood clotting factor V: conversion of factor V to a
prothrombin-binding protein. Biochim. Biophys. Acta, Protein Struct.
1973, 310, 289−294.
(22) Luckow, E. A.; Lyons, D. A.; Ridgeway, T. M.; Esmon, C. T.; Laue,
T. M. Interaction of clotting factor V heavy chain with prothrombin and
prethrombin 1 and role of activated protein C in regulating this
interaction: analysis by analytical ultracentrifugation. Biochemistry 1989,
28, 2348−2354.
(23) Anderson, P. J.; Nesset, A.; Dharmawardana, K. R.; Bock, P. E.
Characterization of proexosite I on prothrombin. J. Biol. Chem. 2000,
275, 16428−16434.
(24) Camire, R. M.; Kalafatis, M.; Tracy, P. B. Proteolysis of factor V by
cathepsin G and elastase indicates that cleavage at Arg1545 optimizes
cofactor function by facilitating factor Xa binding. Biochemistry 1998, 37,
11896−11906.
(25) Gerads, I.; Tans, G.; Yukelson, L. Y.; Zwaal, R. F.; Rosing, J.
Activation of bovine factor V by an activator purified from the venom of
Naja naja oxiana. Toxicon 1992, 30, 1065−1079.
(26) Hirbawi, J.; Bukys, M.; Barhoover, M. A.; Erdogan, E.; Kalafatis,
M. Role of the acidic hirudin-like COOH-terminal amino acid region of
factor Va heavy chain in the enhanced function of prothrombinase.
Biochemistry 2008, 47, 7963−7974.
(27) Beck, D. O.; Bukys, M. A.; Singh, L. S.; Szabo, K. A.; Kalafatis, M.
The contribution of amino acid region ASP695-TYR698 of factor V to
procofactor activation and factor Va function. J. Biol. Chem. 2004, 279,
3084−3095.
(28) Bukys, M. A.; Kim, P. Y.; Nesheim, M. E.; Kalafatis, M. A control
switch for prothrombinase: characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates
the rate and pathway for prothrombin activation. J. Biol. Chem. 2006,
281, 39194−39204.
(29) Bakker, H. M.; Tans, G.; Thomassen, M. C. L. G. D.; Yukelson, L.
Y.; Ebberink, R.; Hemker, H. C.; Rosing, J. Functional properties of
human factor Va lacking Asp683-Arg709 domain of the heavy chain. J.
Biol. Chem. 1994, 269, 20662−20667.
(30) Kalafatis, M.; Beck, D. O.; Mann, K. G. Structural requirements
for expression of factor Va activity. J. Biol. Chem. 2003, 278, 33550−
33561.
(31) Bukys, M. A.; Blum, M. A.; Kim, P. Y.; Brufatto, N.; Nesheim, M.
E.; Kalafatis, M. Incorporation of factor Va into prothrombinase is
required for coordinated cleavage of prothrombin by factor Xa. J. Biol.
Chem. 2005, 280, 27393−27401.
(32) Shim, J. Y.; Lee, C. J.; Sangwook, W.; Pedersen, L. G. A model for
the unique role of factor Va A2 domain extension in the human ternary
thrombin-generating complex. Biophys. Chem. 2015, 199, 46−50.
(33) Kim, P. Y.; Manuel, R.; Nesheim, M. E. Differences in
prethrombin-I activation with human or bovine factor Va can be
attributed to the heavy chain. Thromb. Haemostasis 2009, 102, 623−633.
(34) Jenny, R. J.; Pittman, D. D.; Toole, J. J.; Kriz, R. W.; Aldape, R. A.;
Hewick, R. M.; Kaufman, R. J.; Mann, K. G. Complete cDNA and
5537

DOI: 10.1021/acsomega.7b00769
ACS Omega 2017, 2, 5529−5537

